Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.

ABSTRACT:

Background

Approximately 20% to 50% of women diagnosed with hormone receptor-positive breast cancer discontinue endocrine therapy early; most reports come from automated pharmacy data or small self-report evaluations. We conducted a larger self-report evaluation of endocrine therapy discontinuation associated with patient characteristics and therapy-related adverse effects.

Methods

We surveyed 538 women from a single health plan who were diagnosed with early-stage breast cancer from 2002 to 2008 and received endocrine therapy. Women reported adverse effects and reasons for discontinuation via mailed survey; tumor characteristics were obtained via registry linkage. We classified women as discontinuers if they self-reported stopping therapy and their self-reported duration of

SUBMITTER: Aiello Bowles EJ 

PROVIDER: S-EPMC3500489 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature